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Right ventricular failure (RVF) refractory do medical therapy carries a high mortality risk, and circula-
tory support with right ventricular assist device (RVAD) may be a lifesaving option.1-3 While surgical 
RVAD represents a more invasive therapeutical approach that carries about 50% mortality, the use of 
percutaneous RVAD support may improve outcomes. Acute RVF may result from 1) decreased contrac-
tility due to RV myocardial infarction or myocarditis; 2) volume overload, i.e. increase in preload due to 
excessive transfusions or following LVAD implantation; 3) pressure overload, i.e. increase in afterload 
during hypoxia, acidosis, or positive pressure ventilation. RV displays distinctive features in compari-
son to LV, including high complaint and low resistant pulmonary circulation. Accordingly, RV is more 
sensitive to an increase in afterload. Treatment of acute RVF includes specific causative treatment, 
optimization of preload, management of arrhythmia, reduction of afterload, and augmentation of con-
tractility. If RVF is refractory, it is crucial to consider mechanical circulatory support on time. Percu-
taneous RV support includes VA-ECMO, Impella RP axial pump, and ProtekDuo cannula with an extra-
corporeal centrifugal pump. The selection of the device depends on whether RVF is isolated or part of 
biventricular failure, and whether it is a consequence of pulmonary artery (PA) disease. Percutaneous 
or surgically implanted RVAD is an option in isolated RV failure. Although ECMO can be also used in 
this setting, it is the device of choice if RVF is a consequence of PA disease. In the case of biventricular 
failure, a patient can be supported with paracorporeal surgically implanted or percutaneous BiVAD or 
ECMO. Support in RVF may be a bridge-to-recovery, bridge-to-candidacy, bridge-to-heart transplanta-
tion, or bridge-to-permanent RVAD. RECOVER RIGHT study showed 73% survival in patients supported 
with Impella RP. The Protek Duo cannula with internal jugular cannulation allows early ambulation 
during support. It is crucial to understand the pathophysiology of RVF, i.e. recognize ventricular in-
terdependence with impaired LV filling to avoid futile therapeutical strategies like excessive volume 
infusion, and to start with mechanical support before irreversible multiorgan failure develops.
LITERATURE
1. Kremer J, Farag M, Brcic A, Zubarevich A, Schamroth J, Kreusser MM, et al. Temporary right ventricular circulatory support following right 
ventricular infarction: results of a groin-free approach. ESC Heart Fail. 2020 Oct;7(5):2853-2861. https://doi.org/10.1002/ehf2.12888
2. Anderson MB, Goldstein J, Milano C, Morris LD, Kormos RL, Bhama J, et al. Benefits of a novel percutaneous ventricular assist device for right 
heart failure: The prospective RECOVER RIGHT study of the Impella RP device. J Heart Lung Transplant. 2015 Dec;34(12):1549-60. 
https://doi.org/10.1016/j.healun.2015.08.018
3. Konstam MA, Kiernan MS, Bernstein D, Bozkurt B, Jacob M, Kapur NK, et al; American Heart Association Council on Clinical Cardiology; Council 
on Cardiovascular Disease in the Young; and Council on Cardiovascular Surgery and Anesthesia. Evaluation and Management of Right-Sided 
Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2018 May 15;137(20):e578-e622. 
https://doi.org/10.1161/CIR.0000000000000560
